The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport

被引:114
|
作者
Cheeseman, CI
Tsang, R
机构
关键词
intestinal transport; gastrointestinal hormones; hexose transport; gastric inhibitory polypeptide;
D O I
10.1152/ajpgi.1996.271.3.G477
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The effect of gastric inhibitory poly-peptide (GIP) and the related glucagon-like peptides-1 and -2 (GLP-1 and GLP-2) on jejunal basolateral membrane glucose transport was investigated to determine if the upregulation produced by luminal hexoses could be explained by the release of one or more of these peptides. Luminal perfusion of the rat jejunum for 4 h, under pentobarbital sodium anesthesia, with 100 mM D-glucose produced a significant increase in plasma GIP levels. Vascular infusion of saline containing 100-800 pM GIP also increased the maximal transport rate for carrier-mediated glucose uptake in jejunal basolateral membrane vesicles. The effect of vascular 400 pM GIP was maximal after 1 h and maintained out to 4 h. The effect of luminal glucose could be blocked by preinjection with anti-GIP antibodies, whereas an antineurotensin antibody had no effect. Vascular infusion with 800 pM GLP-1-(7-36) amide had no effect, but GLP-2 (400 and 800 pM) increased the D-glucose maximal transport rate. An anti-GLP antibody was able to block the response to luminal glucose.
引用
收藏
页码:G477 / G482
页数:6
相关论文
共 50 条
  • [31] SPECIFIC BIOLOGIC EFFECTS OF INTESTINAL GLUCAGON-LIKE MATERIALS
    GUTMAN, RA
    FINK, G
    VOYLES, N
    SELAWRY, H
    PENHOS, JC
    LEPP, A
    RECANT, L
    JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (05): : 1165 - 1175
  • [32] Glucagon-like peptides agonists promote maturation of intestinal organoids derived from neonates with necrotizing enterocolitis
    Biouss, George
    Lee, Carol
    Li, Bo
    Adeli, Khosrow
    Pierro, Agostino
    PEDIATRIC SURGERY INTERNATIONAL, 2025, 41 (01)
  • [33] Glucagon-like peptides I and 2 in health and disease: A review
    Marathe, Chinmay S.
    Rayner, Christopher K.
    Jones, Karen L.
    Horowitz, Michael
    PEPTIDES, 2013, 44 : 75 - 86
  • [34] ROLE OF ENDOGENOUS GLUCAGON-LIKE PEPTIDES 1 AND 2 IN OSTEOPOROSIS
    Montes, C.
    Martinez, M.
    Tenorio, C.
    Garrido, M.
    Segarra, A.
    Prieto, I.
    Delgado, M.
    Soriano, R.
    De Damas, M.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S310 - S310
  • [35] LIPOLYTIC ACTION OF GLUCAGON-LIKE PEPTIDES IN ISOLATED RAT ADIPOCYTES
    RUIZGRANDE, C
    ALARCON, C
    MERIDA, E
    VALVERDE, I
    PEPTIDES, 1992, 13 (01) : 13 - 16
  • [36] Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis
    Drucker, DJ
    MOLECULAR ENDOCRINOLOGY, 2003, 17 (02) : 161 - 171
  • [37] The glucagon-like peptides: a double-edged therapeutic sword?
    Perry, T
    Greig, NH
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (07) : 377 - 383
  • [38] Review article: a comparison of glucagon-like peptides 1 and 2
    Janssen, P.
    Rotondo, A.
    Mule, F.
    Tack, J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (01) : 18 - 36
  • [39] Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets
    Cottrell, JJ
    Stoll, B
    Buddington, RK
    Stephens, JE
    Cui, L
    Chang, X
    Burrin, DG
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 290 (02): : G293 - G300
  • [40] DIFFERENCES IN GLUCAGON-LIKE PEPTIDE-1 AND GIP RESPONSES FOLLOWING SUCROSE INGESTION
    FUKASE, N
    TAKAHASHI, H
    MANAKA, H
    IGARASHI, M
    YAMATANI, K
    DAIMON, M
    SUGIYAMA, K
    TOMINAGA, M
    SASAKI, H
    DIABETES RESEARCH AND CLINICAL PRACTICE, 1992, 15 (03) : 187 - 195